Details of Disease

General Information of Disease (ID: DISX2OUL)

• Disease Name: Hodgkin lymphoma
• Synonyms: lymphoma, Hodgkin's; Hodgkin's sarcoma; stage I subdiaphragmatic Hodgkin lymphoma; stage II subdiaphragmatic Hodgkin lymphoma; Hodgkin's Disease; HL; Hodgkins lymphoma; Hodgkin disease; Hodgkin lymphoma; Hodgkin's disease; Hodgkin's lymphoma
• Disease Class: 2B30: Hodgkin lymphoma
• Definition: Hodgkin lymphoma (HL) is a heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma involves primarily lymph nodes.
• Disease Hierarchy:
  DISN6V4S: Lymphoma
  DISUUNPX: Epstein-Barr virus-associated malignant lymphoproliferative disorder
  DISX2OUL: Hodgkin lymphoma
• ICD Code:
  ICD-11: ICD-11: 2B30
  ICD-10: ICD-10: C81, C81.9
  ICD-9: ICD-9: 201
  Expand ICD-11: '2B30
  Expand ICD-10: 'C81; 'C81.9
  Expand ICD-9: 201

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 7 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bleomycin	DMNER5S	Approved	Small molecular drug	[1]
Brentuximab vedotin	DMWLC57	Approved	Monoclonal antibody	[2]
Gallium Citrate Ga-67	DMWQ207	Approved	Small molecular drug	[3]
Mechlorethamine	DM0CVXA	Approved	Small molecular drug	[4]
Procarbazine	DMIK367	Approved	Small molecular drug	[5]
Sintilimab	DMGWR0C	Approved	Antibody	[6]
Tislelizumab	DMGVUO5	Approved	Monoclonal antibody	[7]

This Disease is Treated as An Indication in 18 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Adcetris	DMEDF2B	Phase 3	NA	[8]
NiCord	DMTSURO	Phase 3	NA	[9]
ADCT-301	DMY78E0	Phase 2	NA	[10]
AFM13	DMN45IC	Phase 2	Antibody	[11]
AZD7789	DMOIHWI	Phase 2	Antibody	[12]
Baltaleucel-T	DM3WCL4	Phase 2	NA	[13]
JNJ-40346527	DM219SF	Phase 2	NA	[14]
Oprozomib	DM16RIC	Phase 2	Small molecular drug	[9]
phorbol 12-myristate 13-acetate	DMJWD62	Phase 2	Small molecular drug	[8]
TT11X	DMW3M7X	Phase 2	CAR-T cell therapy	[15]
Anti-CD19 CAR T cells	DMS326R	Phase 1/2	CAR T Cell Therapy	[16]
CART30	DMLE8T9	Phase 1/2	CAR T Cell Therapy	[17]
Anti-CD30-CAR T cells	DM2IEB7	Phase 1	CAR T Cell Therapy	[18]
CAR CD30 T cells	DM8NLPI	Phase 1	CAR T Cell Therapy	[19]
CD30 CAR T Cells	DM4VCJA	Phase 1	CAR T Cell Therapy	[20]
CHT-25	DMJLZ8T	Phase 1	NA	[21]
ICAR30 T cells	DM3YZCV	Phase 1	CAR T Cell Therapy	[22]
MK-8776	DMAS1RB	Phase 1	Small molecular drug	[23]

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Thymocartin	DMQWU5P	Discontinued in Phase 3	Small molecular drug	[24]
EBV-related Hodgkin's disease vaccine	DMX83BV	Terminated	NA	[26]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CART19 cells	DMFRA38	Phase 0	CAR T Cell Therapy	[25]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6772).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7218).
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7278).
• [6] Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
• [7] Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] ClinicalTrials.gov (NCT04052997) Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma. U.S. National Institutes of Health.
• [11] ClinicalTrials.gov (NCT02321592) GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma. U.S. National Institutes of Health.
• [12] ClinicalTrials.gov (NCT05216835) A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma. U.S.National Institutes of Health.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] ClinicalTrials.gov (NCT01597739) A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy. U.S. National Institutes of Health.
• [15] Clinical pipeline report, company report or official report of Tessa Therapeutics
• [16] ClinicalTrials.gov (NCT02277522) CD19 Redirected Autologous T Cells for Hodgkin Lymphoma
• [17] ClinicalTrials.gov (NCT02259556) CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
• [18] ClinicalTrials.gov (NCT03049449) T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
• [19] ClinicalTrials.gov (NCT01316146) Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)
• [20] ClinicalTrials.gov (NCT02917083) CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
• [21] A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. Clin Cancer Res. 2009 Dec 15;15(24):7701-7710.
• [22] ClinicalTrials.gov (NCT03383965) CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas
• [23] ClinicalTrials.gov (NCT00779584) A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248). U.S. National Institutes of Health.
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003196)
• [25] ClinicalTrials.gov (NCT02624258) Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma
• [26] Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood. 2003 Apr 15;101(8):3150-6.